Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
Titel:
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
Auteur:
Yeo, W. Boyer, M. Chung, H. C. Ong, S. Y. K. Lim, R. Zee, Benny Ma, B. Lam, K. C. Mo, F. K. F. Ng, E. K. W. Ho, R. Clarke, S. Roh, J. K. Beale, P. Rha, S. Y. Jeung, H. C. Soo, R. Goh, B. C. Chan, A. T. C.